A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
NCT ID: NCT07169695
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2026-03-02
2027-01-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis
NCT00426023
Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group
NCT01768312
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT02688556
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
NCT00349466
Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears
NCT07234318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T1695
The participant should instill T1695.
Slit Lamp Examination
The participant will have a slit lamp examination
Far Best Corrected Visual Acuity (BCVA)
The participant 's BCVA will be evaluated.
T1695
The participant should instill T1695.
Corneal fluorescein staining score on modified Oxford scale
One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.
Ciclosporin
The participant should instill Ciclosporin.
Slit Lamp Examination
The participant will have a slit lamp examination
Far Best Corrected Visual Acuity (BCVA)
The participant 's BCVA will be evaluated.
Ciclosporin
The participant should instill Ciclosporin.
Corneal fluorescein staining score on modified Oxford scale
One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Slit Lamp Examination
The participant will have a slit lamp examination
Far Best Corrected Visual Acuity (BCVA)
The participant 's BCVA will be evaluated.
T1695
The participant should instill T1695.
Ciclosporin
The participant should instill Ciclosporin.
Corneal fluorescein staining score on modified Oxford scale
One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female participant from 4 years to less than 18 years old.
* Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.
Exclusion Criteria
4 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoires Thea
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-521567-12-00
Identifier Type: CTIS
Identifier Source: secondary_id
LT1695-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.